TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024
- Written by PR Newswire
 |
- TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-life in a Phase 1 study than that of NovoSeven, a conventional hemophilia treatment for patients who develop inhibitors
- TiumBio presented interim Phase 1a clinical data of TU7710 and discussed potential partnership at the ISTH 2024
SEONGNAM, South Korea, Jun...
